aripiprazole has been researched along with clozapine in 217 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.46) | 18.2507 |
| 2000's | 90 (41.47) | 29.6817 |
| 2010's | 104 (47.93) | 24.3611 |
| 2020's | 22 (10.14) | 2.80 |
| Authors | Studies |
|---|---|
| Ernsberger, P; Hufeisen, SJ; Jayathilake, K; Kroeze, WK; Meltzer, HY; Popadak, BA; Renock, SM; Roth, BL; Steinberg, S | 1 |
| Glennon, RA | 1 |
| Huang, AS; Kim, SF; Snowman, AM; Snyder, SH; Teuscher, C | 1 |
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Andreasen, JT; Bernetti, M; Borriello, M; Brindisi, M; Butini, S; Cagnotto, A; Campiani, G; Ceres, N; Coccone, SS; De Angelis, M; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Mennini, T; Mikkelsen, JD; Nacci, V; Novellino, E; Ros, S; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Antonio, CB; Barreiro, EJ; Fraga, CA; Grazziottin, LR; Menegatti, R; Neves, G; Noël, F; Rates, SM; Vieira, RO | 1 |
| Borrelli, G; Butini, S; Campiani, G; Fattorusso, C; Fiorini, I; Franceschini, S; Gemma, S; Guarino, E; Jacobsen, TA; Kumar, V; Madsen, K; Novellino, E; Orteca, N; Persico, M; Sandager-Nielsen, K; Scheel-Kruger, J; Trotta, F | 1 |
| Jensen, AA; Kehler, J; Krogsgaard-Larsen, N | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bienkowski, P; Bucki, A; Jaśkowska, J; Kazek, G; Kowalski, P; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Mitka, K; Pawłowski, M; Siwek, A; Wasik, A; Wesołowska, A | 1 |
| Andreassi, M; Brindisi, M; Brogi, S; Butini, S; Cagnotto, A; Campiani, G; Casagni, A; Franceschini, S; Gemma, S; Gorelli, B; Mikkelsen, JD; Novellino, E; Ros, S; Salmona, M; Sandager-Nielsen, K; Saponara, S; Scheel-Kruger, J; Trotta, F; Weikop, P | 1 |
| Bienkowski, P; Bucki, A; Jastrzębska-Więsek, M; Kazek, G; Kołaczkowski, M; Marcinkowska, M; Mierzejewski, P; Partyka, A; Pawłowski, M; Siwek, A; Śniecikowska, J; Wasik, A; Wesołowska, A | 1 |
| Deng, X; Fu, W; Guo, L; Xu, L; Yu, K; Zhao, W; Zhen, X | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ablordeppey, SY; Adkins, AA; Bricker, BA; Etukala, JR; Huang, XP; Jordan, KR; Kang, HJ; Ofori, E; Peprah, K; Roth, BL; Zhu, XY | 1 |
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Azmanova, M; Barry, NPE; Pitto-Barry, A | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Bojarski, AJ; Dehaen, W; Janousek, J; Juza, R; Karasova, JZ; Kobrlova, T; Korabecny, J; Kubacka, M; Mezeiova, E; Mogilski, S; Musilek, K; Pejchal, J; Petrasek, T; Prchal, L; Randakova, A; Satala, G; Soukup, O; Stark, H; Stefkova-Mazochova, K; Svozil, D; Vlcek, P; Vojtechova, I | 1 |
| Fukamauchi, F; Kito, S; Mataga, N; Miyoshi, R; Sakai, M; Semba, J | 1 |
| Albert, MJ; Baldessarini, RJ; Centorrino, F; Kelleher, JP | 1 |
| Kalkman, HO; Loetscher, E | 1 |
| Hedges, D; Jeppson, K; Whitehead, P | 1 |
| Tamminga, CA | 1 |
| Buckley, PF; Glazer, W; Sebastian, CS | 1 |
| Buchanan, RW; Buckley, PF; Chiles, JA; Conley, RR; Crismon, ML; Ereshefsky, L; Essock, SM; Finnerty, M; Hall, CS; Marder, SR; McEvoy, JP; Miller, A; Miller, DD; Rush, AJ; Saeed, SA; Schooler, NR; Shon, SP; Stroup, S; Tarin-Godoy, B | 1 |
| Bowers, MB; Cooper, C; Lim, S; Pralea, C; Schnitt, J | 1 |
| Bryois, Ch; Sahli, Ch | 1 |
| Citrome, L; Volavka, J | 1 |
| Finkel, S | 1 |
| Katz, IR | 1 |
| Keck, PE | 1 |
| DeQuardo, JR | 1 |
| Dubois, D | 1 |
| Cosi, C; Newman-Tancredi, A; Rollet, K; Tesori, V; Waget, A | 1 |
| Kuehn, BM | 1 |
| Bruins Slot, LA; Kleven, MS; Newman-Tancredi, A | 1 |
| Fabbri, D; Heidbreder, CA; Zocchi, A | 1 |
| Ball, MP; Cates, ME; Hooper, ET; Skipwith, DF | 1 |
| Berk, M; Bourin, M; Dodd, S; Ivanovski, B; Lagopoulos, J; Malhi, GS; Mitchell, PB | 1 |
| Calliess, IT; Kropp, S; Sieberer, M; Ziegenbein, M | 1 |
| Balit, CR; Isbister, GK; Kilham, HA | 1 |
| Annable, L; Beauclair, L; Chouinard, G; Kolivakis, TT; Margolese, HC; Miller, R | 1 |
| Borba, CP; Cather, C; Daley, TB; Evins, AE; Freudenreich, O; Goff, DC; Henderson, DC; Kunkel, L; Louie, PM; Nguyen, DD | 1 |
| Baciu, D; Walther, S | 1 |
| Assié, MB; Carilla-Durand, E; Cosi, C; Leduc, N; Maraval, M; Newman-Tancredi, A; Ormiere, AM | 1 |
| Hara, C; Rocha, FL | 1 |
| Clarke, LA; Kaushik, S; Lindenmayer, JP | 1 |
| Doraiswamy, PM; Levine, JG; Szarfman, A; Tonning, JM | 1 |
| Bies, RR; Chew, ML; Gharabawi, G; Greenspan, A; Kapur, S; Kirshner, MA; Lehman, ME; Mulsant, BH; Pollock, BG | 1 |
| Dekeyne, A; Iob, L; Millan, MJ; Péglion, JL | 1 |
| Harborne, GC; Karunakaran, K; Tungaraza, TE | 1 |
| Correll, CU; Frederickson, AM; Kane, JM; Manu, P | 1 |
| Dimopoulos, NP; Kararizou, EG; Katsa, AN; Katsanou, MN; Mitropoulos, PA; Mitsonis, CI; Tsakiris, FE | 1 |
| Abu-Tair, F; Bergemann, N; Kopitz, J | 1 |
| Kropp, S; Wittmann, G; Ziegenbein, M | 1 |
| Barlow, KB; Kapur, S; Natesan, S; Nobrega, JN; Reckless, GE | 1 |
| De Oliveira, IR; Juruena, MF | 1 |
| Engel, JA; Fejgin, K; Klamer, D; Pålsson, E; Safonov, S; Svensson, L; Wass, C | 1 |
| Keller Ashton, A | 1 |
| Limosin, F | 1 |
| Knopf, U; Kuwilsky, A; Zink, M | 1 |
| Bowers, MB; Lim, S | 1 |
| Corsini, GU; Maggio, R; Millan, MJ; Novi, F | 1 |
| Assis, LC; Barbosa, LM; Grandi, E; Quevedo, J; Rezin, GT; Streck, EL | 1 |
| Wooten, J | 1 |
| Hurtig, HI; Weintraub, D | 1 |
| Berges, A; Dahmen, MM; Petry, WM; Stoner, SC | 1 |
| Avorn, J; Brookhart, MA; Choudhry, NK; Mogun, H; Patrick, A; Schneeweiss, S; Setoguchi, S; Wang, PS | 1 |
| Bachmann, CJ; de Lange, D; Nicksch, B; Remschmidt, H; Theisen, FM | 1 |
| Bushe, CJ; Leonard, BE | 1 |
| Chen, YY; Hung, GC | 1 |
| Hughes, D; Morcos, M | 1 |
| De Hert, M; Hanssens, L; Peuskens, J; Scheen, A; Van Eyck, D; van Winkel, R; Wampers, M | 1 |
| Dal-Pizzol, F; Gomes, KM; Martins, MR; Petronilho, FC; Quevedo, J; Streck, EL | 1 |
| Ahn, YM; Chang, JS; Kang, UG; Kim, SH; Kim, YS; Lee, KY; Park, HJ | 1 |
| Englisch, S; Zink, M | 1 |
| Andreazza, AC; Kapczinski, F; Quevedo, J; Rosa, MI; Stertz, L; Streck, EL; Valvassori, SS | 1 |
| Erickson, CA; McDougle, CJ; Posey, DJ; Stigler, KA | 1 |
| Sikich, L | 1 |
| Croarkin, PE; Emslie, GJ; Mayes, TL | 1 |
| Aliaga, M; Assié, MB; Barbara, M; Bardin, L; Carilla-Durand, E; Malfètes, N; Maraval, M; Newman-Tancredi, A | 1 |
| Bogeski, M; Gogos, A; van den Buuse, M | 1 |
| Bruggeman, R; Postema, R; Schilthuis, M; Schorr, SG; Slooff, CJ; Taxis, K; Van Oven, W | 1 |
| Libiger, J; Masopust, J; Tůma, I | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Perini, GI; Pigato, G; Toffanin, T | 1 |
| Azzoni, A; Raja, M | 1 |
| Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS | 1 |
| Hauser, D; Ladds, B; Mejia, C; Thomas, P | 1 |
| Jong-Yih, L | 1 |
| Cho, DY; Lindenmayer, JP | 1 |
| Bogers, JP; Starrenburg, FC | 1 |
| Carlström, EL; Jazin, E; Jiang, L; Saetre, P | 1 |
| Kumar, R; Sachdev, PS | 1 |
| Accordini, S; Artioli, P; Barale, F; Barbui, C; Beneduce, R; Berardi, D; Bertolazzi, G; Biancosino, B; Bisogno, A; Bivi, R; Bogetto, F; Boso, M; Bozzani, A; Bucolo, P; Casale, M; Cascone, L; Ciammella, L; Cicolini, A; Cipresso, G; Cipriani, A; Colombo, P; Dal Santo, B; De Francesco, M; Di Lorenzo, G; Di Munzio, W; Ducci, G; Erlicher, A; Esposito, E; Ferrannini, L; Ferrato, F; Ferro, A; Fragomeno, N; Frova, M; Gardellin, F; Garzotto, N; Giambartolomei, A; Giupponi, G; Grassi, L; Grazian, N; Grecu, L; Guerrini, G; Laddomada, F; Lazzarin, E; Lintas, C; Malchiodi, F; Malvini, L; Marchiaro, L; Marsilio, A; Mauri, MC; Mautone, A; Menchetti, M; Migliorini, G; Mollica, M; Moretti, D; Mulè, S; Nicholau, S; Nosè, F; Nosè, M; Occhionero, G; Pacilli, AM; Parise, VF; Pecchioli, S; Percudani, M; Piantato, E; Piazza, C; Pontarollo, F; Pycha, R; Quartesan, R; Rillosi, L; Risso, F; Rizzo, R; Rocca, P; Roma, S; Rossattini, M; Rossi, G; Sala, A; Santilli, C; Saraò, G; Sarnicola, A; Sartore, F; Scarone, S; Sciarma, T; Siracusano, A; Strizzolo, S; Tansella, M; Targa, G; Tasser, A; Tomasi, R; Travaglini, R; Veronese, A; Ziero, S | 1 |
| Chiu, NY; Hsu, WY; Kahn, DA; Lee, CI | 1 |
| Auclair, AL; Barret-Grévoz, C; Barreto, M; Depoortère, R; Kleven, MS; Newman-Tancredi, A | 1 |
| DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU | 1 |
| Cohen, D; Correll, CU | 1 |
| Bachmann, CJ; Lehr, D; Preiss, M; Theisen, FM | 1 |
| Avenet, P; Bergis, O; Boulay, D; Griebel, G | 1 |
| de Haan, L; Peters, B | 1 |
| Gagliano, A; Masi, G | 1 |
| Dassa, D; Drai-Moog, D; Samuelian, JC | 1 |
| Conley, Y; Davies, MA; Roth, BL | 1 |
| Kim, CE; Lee, MJ | 1 |
| Helm, ME; Henderson, C; Martin, BC; Pathak, P; West, D | 1 |
| Chen, HK; Shao, CH; Wu, BJ | 1 |
| Asenbaum, S; Barnas, C; Fischer, P; Mossaheb, N; Spindelegger, C | 1 |
| Duggan, L; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Radics, J | 1 |
| Dewaele, P; Fleischhacker, WW; Heikkinen, ME; Hennicken, D; Kerselaers, W; Landsberg, W; Loze, JY; McQuade, RD; Olié, JP | 1 |
| Elsom, SJ; Gurvich, C; Kulkarni, J; McCauley-Elsom, K | 1 |
| Brunetti, L; Patel, MK | 1 |
| Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Chen, CH; Chiu, YH; Lu, ML | 1 |
| Claes, S; De Hert, M; Martens, GJ; Moons, T; Peuskens, J; Van Loo, KM; Van Schijndel, JE; van Winkel, R | 1 |
| Hunger, H; Kissling, W; Komossa, K; Leucht, S; Rummel-Kluge, C; Schmid, F; Schwarz, S | 1 |
| Bruno, A; Di Nardo, F; Micò, U; Muscatello, MR; Pandolfo, G; Santoro, V; Scimeca, G; Spina, E; Zoccali, RA | 1 |
| Bernagie, C; De Hert, M; Dockx, L; Leucht, S; Peuskens, B; Peuskens, J; Sweers, K; Tack, J; Van de Straete, S; Wampers, M | 1 |
| De Risio, A; Gentile, B; Giannarelli, D; Pancheri, A; Simonetti, G; Stefanutto, L | 1 |
| Englisch, S; Esslinger, C; Meyer-Lindenberg, A; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Accordini, S; Barbui, C; Cipriani, A; Esposito, E; Girlanda, F; Nosè, M; Purgato, M; Stroup, S; Tansella, M; Veronese, A | 1 |
| Breton, C; Delahaye, F; Dickes-Coopman, A; Dutriez-Casteloot, I; Guillemot, J; Laborie, C; Lesage, J; Lukaszewski, MA; Mayeur, S; Montel, V; Vieau, D | 1 |
| Andel, R; Becker, MA; Boaz, TL; Chandler, K; Desmarais, SL; Howe, A; Van Dorn, RA | 1 |
| Fagiolini, A; Frieri, T; Villari, V | 1 |
| Alexopoulos, GS; Avari, J; Mahgoub, N | 1 |
| Bertani, S; Carboni, L; Cavanni, P; Fratte, SD; Michielin, F; Negri, M; Oliosi, B | 1 |
| Forbes, RA; Kikuchi, T; McQuade, RD; Tadori, Y | 1 |
| Faludi, G; Fejes, L; Inczédy-Farkas, G; Kassai-Farkas, A; Lazáry, J; Makkos, Z | 1 |
| Body, S; Bradshaw, CM; de Bruin, N; den Boon, FS; Hampson, CL; Szabadi, E | 1 |
| Berkowitz, RL; Docherty, JP; Ni, Q; Parks, JJ; Patel, U | 1 |
| Itoh, M; Kaneko, YS; Kondo, K; Mori, K; Nagasaki, H; Nagatsu, T; Nakashima, A; Ota, A; Ota, M; Takayanagi, T | 1 |
| Johnsen, E; Kroken, RA | 1 |
| Meltzer, HY; Porter, JH; Vunck, SA; Wiebelhaus, JM | 1 |
| Fleischhacker, WW; Uchida, H | 1 |
| Azorin, JM; Gasquet, I; Gierski, F; Leguay, D; Lemogne, C; Limosin, F; Raucher-Chéné, D; Rouillon, F; Schuster, JP | 1 |
| Borba, CP; Copeland, P; Fan, X; Freudenreich, O; Goff, DC; Hayden, D; Henderson, DC | 1 |
| Blagojević, D; Lečić-Toševski, D; Miljević, Č; Niketić, V; Nikolić, M; Nikolić-Kokić, A; Spasić, MB | 1 |
| Chang, HC; Chang, LR; Huang, WL; Liu, CM; Tsai, YF | 1 |
| Bader, M; Klingerman, CM; Lynch, CJ; Stipanovic, ME | 1 |
| Ananjit, S; Badiah, Y; Bulgiba, A; Habil, MH; Hairi, NN; Haslina, MY; Hatim, A; Mahmud, B; Ramli, MA; Said, MA; Sapini, Y; Shah, M; Zafidah, W | 1 |
| Honaker, J; Lohr, WD | 1 |
| Couchman, L; Fisher, DS; Flanagan, RJ; Handley, SA; Morgan, PE; Partridge, SJ | 1 |
| Dell'Osso, L; Marazziti, D; Moroni, I; Piccinni, A; Veltri, A | 1 |
| Fisher, DS; Flanagan, RJ; Handley, SA; Partridge, SJ | 1 |
| Edlinger, M; Fleischhacker, W; Hofer, A; Seppi, K | 1 |
| Gangadhar, BN; Rao, MG; Raveendranathan, D; Shiva, L; Varambally, S; Venkatasubramanian, G | 1 |
| Grossman, F; Hassan, M; Meyer, K; O'Day, K; Rajagopalan, K | 1 |
| Accordini, S; Barbui, C; Cipriani, A; Girlanda, F; Nosè, M; Purgato, M; Tansella, M | 1 |
| Jalenques, I; Kernisant, M; Legrand, G; May, R; Richard, B | 1 |
| Barry, SJ; Gaughan, TM; Hunter, R | 1 |
| Cantisani, A; Ferrari, G; Grassi, G; Pallanti, S; Poli, L; Righi, L | 1 |
| Arnoldy, R; Curtis, J; Samaras, K | 1 |
| Cao, B; Hou, R; Jian, J; Mi, G; Qiu, H; Tang, M; Wang, M | 1 |
| Lu, CL; Shen, YC | 1 |
| Morrissette, DA; Stahl, SM | 1 |
| Goyal, P; Kumar, D; Prakash, O; Tripathi, P | 1 |
| Eifler, S; Englisch, S; Esslinger, C; Kirsch, P; Meyer-Lindenberg, A; Mier, D; Rausch, F; Schirmbeck, F; Zink, M | 1 |
| Aiello, R; Citraro, R; De Sarro, G; Leo, A; Pugliese, M; Russo, E | 1 |
| Maneeton, B; Maneeton, N; Srisurapanont, M; Suttajit, S | 1 |
| Brugnoli, R; De Filippis, S; Di Sciascio, G; Fagiolini, A; Maina, G | 1 |
| Chang, CH; Chang, YC; Chen, YW; Cheng, YS; Chung, W; Tseng, PT; Wang, HY; Wu, CK | 1 |
| Barreiro, EJ; Bosier, B; Fraga, CA; Hermans, E; Menegatti, R; Monteiro do Monte, F; Noël, F; Pompeu, TE | 1 |
| Austin, M; Dadlani, N | 1 |
| Erdogan, A; Gunes, H; Tanidir, C | 1 |
| Ahn, J; Joe, S; Lim, J; Park, C; Park, J | 1 |
| Fernandez-Egea, E; Mané, A; Mann, L; Mundell, C; Ramos Perdigués, S; Sauras Quecuti, R | 1 |
| Cassoli, JS; Guest, PC; Martins-de-Souza, D; Santana, AG | 1 |
| Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M | 1 |
| Flynn, A; Macaluso, M; Preskorn, S | 1 |
| Baymeeva, NV; Burminskiy, DS; Miroshnichenko, II; Morozova, MA; Platova, AI; Potanin, SS | 1 |
| Bruhn, CH; Hashemi, N; Nielsen, J; Polcwiartek, C; Rosenzweig, M; Vang, T | 1 |
| An, FR; Chiu, HF; Jin, X; Li, L; Lok, GK; Ng, CH; Ungvari, GS; Wang, ZM; Wu, PP; Xiang, YT; Yang, R | 1 |
| Barber, S; Cipriani, A; Corsi, M; Olotu, U | 1 |
| Birur, B; Lentowicz, I; Li, L; Rayikanti, R | 1 |
| Akar, FY; Buyukokuroglu, ME; Erden, BF; Mutlu, O; Tanyeri, MH; Tanyeri, P; Ulak, G | 1 |
| Chikama, K; Kajitani, K; Nakabeppu, Y; Tsukamoto, T; Uchimura, N; Yamada, H | 1 |
| Huh, L; Lee, BJ | 1 |
| Arnaout, B; Feeley, RJ; Yoon, G | 1 |
| Dietrich-Muszalska, A; Kolińska-Łukaszuk, J | 1 |
| Kawai, H; Kishimoto, M; Kodama, M; Mizuki, Y; Okahisa, Y; Sakamoto, S; Takaki, M; Yamada, N; Yoshimura, B | 1 |
| Bolea, B; Davies, S; Ijaz, S; Moran, P; Richards, A; Savović, J; Sullivan, S | 1 |
| Dias Alves, M; Micoulaud-Franchi, JA; Simon, N; Vion-Dury, J | 1 |
| Barr, AM; Honer, WG; Kim, DD; Procyshyn, RM; White, RF | 1 |
| Correll, CU; Mehtälä, J; Taipale, H; Tanskanen, A; Tiihonen, J; Vattulainen, P | 1 |
| Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C | 1 |
| Lin, JR; Nakagawasai, O; Nemoto, W; Odaira, T; Onogi, H; Sakuma, W; Srivastava, LK; Takahashi, K; Tan-No, K | 1 |
| De Oliveira, EO; Donahue, TJ; Hillhouse, TM; Porter, JH; Webster, KA | 1 |
| Görtz, P; Henning, U; Lange-Asschenfeldt, C; Theiss, S | 1 |
| Belsham, DD; Hahn, MK; Kanagasundaram, P; Kowalchuk, C; McIntyre, WB | 1 |
| Crippa, A; Davis, JM; Leucht, S; Orsini, N; Patel, MX; Siafis, S | 1 |
| Jovanović, M; Miljković, B; Vučićević, K | 1 |
| Barr, AM; Honer, WG; Kim, DD; Lu, C; Procyshyn, RM; Stewart, SE; White, RF | 1 |
| Chen, Y; Gordon, A; Li, B; Tang, W | 1 |
| Hamada, T; Hata, T; Kanazawa, T; Katsumata, T; Nakajima, M; Nishihara, M; Yoneda, H | 1 |
| Claro, A; Corte-Real, F; Franco, J; Monteiro, C; Mustra, C; Proença, P | 1 |
| Azorin, JM; Simon, N | 1 |
| Liang, J; Shan, F; Zhang, YY; Zhou, XH | 1 |
| Appignanesi, C; Marpepa, B; Orsolini, L; Salvi, V; Volpe, U | 1 |
| Chang, CK; Chen, CH; Chen, PY; Chiu, CC; Fang, SC; Huang, MC; Hwang, LL; Lu, ML; Mondelli, V | 1 |
| Bellagamba, S; Orsolini, L; Salvi, V; Volpe, U | 1 |
| Chen, CH; Chen, PY; Chiu, CC; Hsieh, TH; Huang, CY; Huang, MC; Liu, YR; Lu, ML | 1 |
| Byeon, SJ; Chung, SJ; Oh, S | 1 |
| Osman, E; Yıldız, M | 1 |
| Chiappini, S; Giannantonio, MD; Martinotti, G; Miuli, A; Mosca, A; Pettorruso, M; Santovito, MC; Sensi, SL; Skryabin, V | 1 |
| Arango, C; Leucht, S; Lopez-Morinigo, JD | 1 |
| Berk, M; Bortolasci, CC; Dean, OM; Gray, L; Kidnapillai, S; Kim, JH; Liu, ZSJ; McGee, SL; Panizzutti, B; Richardson, MF; Spolding, B; Swinton, C; Truong, TTT; Walder, K | 1 |
| Argerich, J; Casajuana-Martin, N; Ciruela, F; Del Torrent, CL; Ferré, S; Gómez-Acero, L; Pardo, L; Sahlholm, K; Valle-León, M | 1 |
| Gupta, B; Lee, J; Pilunthanakul, T; Ting, MQJ | 1 |
| Cañete, T; Fernández-Teruel, A; Lavín, V; Oliveras, I; Río-Álamos, C; Sampedro-Viana, D; Sánchez-González, A; Sanna, F; Tapias-Espinosa, C; Tobeña, A; Torrecilla, P | 1 |
50 review(s) available for aripiprazole and clozapine
| Article | Year |
|---|---|
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
Topics: Animals; Humans; Ligands; Receptors, Serotonin; Serotonin Agents; Serotonin Antagonists; Serotonin Receptor Agonists | 2003 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Schizophrenia: synthetic strategies and recent advances in drug design.
Topics: | 2018 |
Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dosage Forms; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2002 |
Antipsychotic medication and seizures: a review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2003 |
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Patient Compliance; Piperazines; Polypharmacy; Quetiapine Fumarate; Quinolones; Research Design; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2004 |
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
Topics: Algorithms; Ambulatory Care; Ambulatory Care Facilities; Antipsychotic Agents; Aripiprazole; Clozapine; Decision Trees; Drug Administration Schedule; Drug Therapy, Combination; Humans; Piperazines; Practice Guidelines as Topic; Quinolones; Schizophrenia; Schizophrenic Psychology; Texas; Thiazoles; Treatment Outcome | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Child; Clozapine; Dibenzothiazepines; Double-Blind Method; Female; Fructose; Haloperidol; Humans; Imidazoles; Indoles; Male; Obesity; Olanzapine; Piperazines; Placebos; Psychotropic Drugs; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Socioeconomic Factors; Sulpiride; Thiazoles; Time Factors; Topiramate; Valproic Acid; Weight Gain | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Serotonin Antagonists; Thiazoles; Treatment Outcome; United States | 2004 |
Optimizing atypical antipsychotic treatment strategies in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Olanzapine; Parkinson Disease; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; Treatment Outcome | 2004 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Double-Blind Method; Humans; Lithium; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2005 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
A typical mood stabilizers: a "typical role for atypical antipsychotics.
Topics: Affect; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Secondary Prevention; Sulpiride; Thiazoles | 2005 |
Antipsychotic poisoning in young children: a systematic review.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Chlorpromazine; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Infant; Infant, Newborn; Olanzapine; Pimozide; Piperazines; Poisoning; Quetiapine Fumarate; Quinolones; Risperidone | 2005 |
Tardive dyskinesia in the era of typical and atypical antipsychotics. Part 2: Incidence and management strategies in patients with schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Dyskinesia, Drug-Induced; Humans; Incidence; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2005 |
Treatment of psychosis: 30 years of progress.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptors, Dopamine; Receptors, Serotonin; Risperidone; Schizophrenia; Thiazoles | 2006 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Presentation and management of psychosis in Parkinson's disease and dementia with Lewy bodies.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Cholinesterase Inhibitors; Clozapine; Controlled Clinical Trials as Topic; Dibenzothiazepines; Humans; Lewy Body Disease; Male; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones | 2007 |
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Humans; Olanzapine; Piperazines; Quinolones; Schizophrenia | 2007 |
Combined antipsychotic treatment involving clozapine and aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Weight Loss | 2008 |
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.
Topics: Adolescent; Aggression; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Benzodiazepines; Child; Child Development Disorders, Pervasive; Child, Preschool; Clozapine; Dibenzothiazepines; Disorders of Excessive Somnolence; Humans; Obesity; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2008 |
Efficacy of atypical antipsychotics in early-onset schizophrenia and other psychotic disorders.
Topics: Adolescent; Adult; Age of Onset; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Diseases; Child; Chronic Disease; Clozapine; Comorbidity; Disease Progression; Humans; Magnetic Resonance Imaging; Olanzapine; Piperazines; Prognosis; Psychotic Disorders; Quinolones; Schizophrenia; Thiazoles; Treatment Failure | 2008 |
Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Humans; Neuroleptic Malignant Syndrome; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Thiazoles | 2008 |
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins.
Topics: Adiponectin; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Diabetes Mellitus; Humans; Leptin; Obesity; Olanzapine; Piperazines; Quinolones; Receptor, Muscarinic M3; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Receptors, Histamine; Serotonin 5-HT1 Receptor Agonists; Thiazoles; Weight Gain | 2009 |
Akathisia and second-generation antipsychotic drugs.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Isoxazoles; Olanzapine; Piperazines; Piperidines; Prevalence; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Sulpiride; Thiazoles | 2009 |
Olanzapine versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2010 |
Antipsychotics in pregnancy.
Topics: Abnormalities, Drug-Induced; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes, Gestational; Dibenzothiazepines; Female; Humans; Infant, Newborn; Olanzapine; Piperazines; Pregnancy; Pregnancy Complications; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinical Trials as Topic; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2010 |
Risperidone versus other atypical antipsychotics for schizophrenia.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Humans; Imidazoles; Indoles; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles | 2011 |
Adding aripiprazole to clozapine worsened delusions and hallucinations: a case report.
Topics: Aripiprazole; Clozapine; Delusions; Drug Therapy, Combination; Female; Hallucinations; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia, Paranoid | 2011 |
Is rational antipsychotic polytherapy feasible? A selective review.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Haloperidol; Humans; Piperazines; Prolactin; Quinolones; Schizophrenia | 2012 |
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Humans; Piperazines; Polypharmacy; Practice Patterns, Physicians'; Quinolones; Schizophrenia | 2014 |
Atypical antipsychotics for the treatment of disruptive behavior.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Drug Interactions; Drug Monitoring; Humans; Olanzapine; Pediatrics; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone | 2013 |
Schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Risperidone; Schizophrenia; Treatment Outcome | 2012 |
Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Dibenzocycloheptenes; Drug Therapy, Combination; Heterocyclic Compounds, 4 or More Rings; Humans; Impulsive Behavior; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Polypharmacy; Psychotic Disorders; Quetiapine Fumarate; Receptors, Dopamine D2; Risperidone; Thiazoles; Violence | 2014 |
Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: a systematic review and meta-analysis of randomized-controlled trials.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Randomized Controlled Trials as Topic; Schizophrenia | 2015 |
Atypical neuroleptic malignant syndrome in patients treated with aripiprazole and clozapine: a case-series study and short review.
Topics: Adult; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Female; Fluoxetine; Hospitalization; Humans; Injections, Intramuscular; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology | 2015 |
Employing proteomics to unravel the molecular effects of antipsychotics and their role in schizophrenia.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Chlorpromazine; Clozapine; Disease Models, Animal; Gene Expression Regulation; Glycolysis; Humans; Mitochondrial Proteins; Nerve Tissue Proteins; Oxidative Phosphorylation; Proteome; Proteomics; Schizophrenia; Treatment Outcome | 2016 |
Diabetic ketoacidosis in patients exposed to antipsychotics: a systematic literature review and analysis of Danish adverse drug event reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Denmark; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Olanzapine; Risk Factors; Risperidone; Young Adult | 2016 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quetiapine Fumarate; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Sulpiride; Thiazoles; Weight Gain | 2017 |
Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Middle Aged; Polypharmacy; Prospective Studies; Schizophrenia; Systematic Reviews as Topic | 2018 |
Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Topics: Acute Disease; Administration, Oral; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Dose-Response Relationship, Drug; Haloperidol; Humans; Imidazoles; Indoles; Isoxazoles; Lurasidone Hydrochloride; Olanzapine; Paliperidone Palmitate; Piperazines; Piperidines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Thiazoles; Thiophenes | 2020 |
Understanding variability in the pharmacokinetics of atypical antipsychotics - focus on clozapine, olanzapine and aripiprazole population models.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Models, Biological; Nonlinear Dynamics; Olanzapine | 2020 |
Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases.
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Obsessive-Compulsive Disorder; Schizophrenia | 2020 |
Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Models, Theoretical; Polypharmacy; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Schizophrenia | 2020 |
Atypical Antipsychotic Drugs in Dual Disorders: Current Evidence for Clinical Practice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Female; Humans; Male; Mice; Olanzapine; Quetiapine Fumarate; Rats; Risperidone | 2022 |
Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Humans; Lurasidone Hydrochloride; Molindone; Olanzapine; Paliperidone Palmitate; Quality of Life; Quetiapine Fumarate; Risperidone; Schizophrenia; Systematic Reviews as Topic | 2022 |
12 trial(s) available for aripiprazole and clozapine
| Article | Year |
|---|---|
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Mass Index; Body Weight; Cholesterol; Clozapine; Community Mental Health Centers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Triglycerides | 2006 |
Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Female; Follow-Up Studies; Humans; Male; Middle Aged; Outpatients; Pilot Projects; Piperazines; Psychiatric Status Rating Scales; Psychometrics; Quinolones; Schizophrenia; Time Factors | 2007 |
Clozapine augmented with aripiprazole in 5 patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2006 |
Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Severity of Illness Index; Surveys and Questionnaires | 2008 |
Treatment of psychotic disorders with aripiprazole in the emergency psychiatric setting.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Diagnostic and Statistical Manual of Mental Disorders; Dibenzothiazepines; Drug Therapy, Combination; Emergency Services, Psychiatric; Female; Humans; Intensive Care Units; Male; Middle Aged; Piperazines; Psychiatric Department, Hospital; Psychiatric Status Rating Scales; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Severity of Illness Index; Treatment Outcome | 2008 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Dibenzothiazepines; Female; Hospitalization; Humans; Male; Middle Aged; Olanzapine; Perphenazine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
Rationale and design of an independent randomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Protocols; Clozapine; Drug Resistance; Drug Therapy, Combination; Government Regulation; Haloperidol; Humans; Italy; Piperazines; Prospective Studies; Quinolones; Research Design; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2009 |
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aripiprazole; Body Mass Index; Body Weight; Chemotherapy, Adjuvant; Cholesterol; Clozapine; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Young Adult | 2010 |
Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Clozapine; Double-Blind Method; Drug Interactions; Female; Humans; Male; Piperazines; Quinolones; Schizophrenia; Time Factors | 2011 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Haloperidol; Humans; Male; Piperazines; Quinolones; Schizophrenia | 2011 |
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia.
Topics: Absorptiometry, Photon; Adult; Antipsychotic Agents; Aripiprazole; Body Composition; Clozapine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Glucose; Glucose Tolerance Test; Humans; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Piperazines; Quinolones; Schizophrenia | 2013 |
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Disease-Free Survival; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Italy; Kaplan-Meier Estimate; Linear Models; Multivariate Analysis; Piperazines; Proportional Hazards Models; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Time Factors; Treatment Outcome | 2013 |
155 other study(ies) available for aripiprazole and clozapine
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Humans; Protein Binding; Receptors, Histamine H1; Statistics, Nonparametric; Weight Gain | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemistry; Mice; Phosphorylation; Receptors, Histamine H1; Weight Gain | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Binding Sites; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mice; Models, Molecular; Molecular Structure; Protein Binding; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2009 |
Searching for multi-target antipsychotics: Discovery of orally active heterocyclic N-phenylpiperazine ligands of D2-like and 5-HT1A receptors.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Cell Line; Humans; Ligands; Male; Mice; Piperazines; Pyrazoles; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia | 2010 |
Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors.
Topics: Animals; Antipsychotic Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Ligands; Mice; Models, Molecular; Piperazines; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Structure-Activity Relationship | 2010 |
Novel 7-phenylsulfanyl-1,2,3,4,10,10a-hexahydro-pyrazino[1,2-a]indoles as dual serotonin 5-HT2C and 5-HT6 receptor ligands.
Topics: Cell Line; HeLa Cells; Humans; Indoles; Ligands; Protein Binding; Pyrazines; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel arylsulfonamide derivatives with 5-HT₆/5-HT₇ receptor antagonism targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Avoidance Learning; Benzoxazoles; Catalepsy; CHO Cells; Cricetulus; Dementia; Dopamine D2 Receptor Antagonists; HEK293 Cells; Humans; Male; Models, Molecular; Motor Activity; Radioligand Assay; Rats, Wistar; Receptors, Serotonin; Serotonin Antagonists; Structure-Activity Relationship; Sulfonamides | 2014 |
Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: synthesis, biological characterization, and behavioral studies.
Topics: Amides; Animals; Antipsychotic Agents; Behavior, Animal; Dizocilpine Maleate; Dopamine Antagonists; Drug Evaluation, Preclinical; Female; Kinetics; Ligands; Male; Mice; Prefrontal Cortex; Protein Binding; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D3; Schizophrenia; Serotonin Receptor Agonists; Structure-Activity Relationship | 2014 |
Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia.
Topics: Animals; Benzamides; Dementia; Dose-Response Relationship, Drug; Drug Partial Agonism; Humans; Indoles; Ligands; Male; Models, Molecular; Molecular Structure; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine D2; Receptors, Serotonin; Structure-Activity Relationship; Swimming | 2015 |
Discovery of novel potent and selective ligands for 5-HT2A receptor with quinazoline scaffold.
Topics: Dose-Response Relationship, Drug; Drug Discovery; Humans; Ligands; Molecular Structure; Quinazolines; Receptor, Serotonin, 5-HT2A; Serotonin 5-HT2 Receptor Antagonists; Structure-Activity Relationship | 2015 |
Design and synthesis of dual 5-HT1A and 5-HT7 receptor ligands.
Topics: Carbon-13 Magnetic Resonance Spectroscopy; Isoquinolines; Ligands; Proton Magnetic Resonance Spectroscopy; Receptor, Serotonin, 5-HT1A; Receptors, Serotonin | 2016 |
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
Differential expression of c-fos mRNA in rat prefrontal cortex, striatum, N. accumbens and lateral septum after typical and atypical antipsychotics: an in situ hybridization study.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Brain; Clozapine; Corpus Striatum; Fluphenazine; Genes, fos; Haloperidol; In Situ Hybridization; Nucleus Accumbens; Piperazines; Prefrontal Cortex; Quinolones; Rats; RNA, Messenger; Septum Pellucidum; Sulpiride | 1996 |
alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brimonidine Tartrate; Chlorpromazine; CHO Cells; Clozapine; Cricetinae; Cyclic AMP; Dibenzothiazepines; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Gene Expression; Haloperidol; Humans; Isoxazoles; Norepinephrine; Olanzapine; Piperazines; Piperidines; Pirenzepine; Quetiapine Fumarate; Quinolones; Quinoxalines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D2; Risperidone; Thiazoles; Transfection; Yohimbine | 2003 |
Similarities and differences among antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Haloperidol; Humans; Olanzapine; Piperazines; Pirenzepine; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2003 |
Possible increased efficacy of low-dose clozapine when combined with aripiprazole.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2004 |
[Expectations and developments in atypical antipsychotics].
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Clozapine; Diabetes Complications; Haloperidol; Humans; Obesity; Olanzapine; Piperazines; Quinolones; Risk Factors; Schizophrenia; Weight Gain | 2004 |
Increased efficacy with addition of clozapine to aripiprazole: alternative explanations.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2005 |
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
Topics: Aminopyridines; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Corpus Striatum; Disease Models, Animal; Excitatory Amino Acid Agonists; Haloperidol; Kainic Acid; Male; Mice; Mice, Inbred C57BL; Piperazines; Piperidines; Pyridines; Quinolones; Receptor, Serotonin, 5-HT1A; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Serotonin Antagonists; Thiazoles | 2005 |
FDA warns antipsychotic drugs may be risky for elderly.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dementia; Dibenzothiazepines; Drug Approval; Drug Labeling; Humans; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2005 |
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dioxanes; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Excitatory Amino Acid Antagonists; Haloperidol; Interpersonal Relations; Male; Phencyclidine; Piperazines; Pyridines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Remoxipride; Serotonin Antagonists; Serotonin Receptor Agonists; Thiazoles; Tropanes | 2005 |
Aripiprazole increases dopamine but not noradrenaline and serotonin levels in the mouse prefrontal cortex.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dopamine; Dose-Response Relationship, Drug; Extracellular Fluid; Male; Mice; Mice, Inbred C57BL; Microdialysis; Motor Activity; Norepinephrine; Piperazines; Prefrontal Cortex; Quinolones; Serotonin; Synaptic Transmission; Up-Regulation | 2005 |
Clozapine-induced hyperlipidemia resolved after switch to aripiprazole therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cholesterol; Clozapine; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Piperazines; Psychotic Disorders; Quinolones | 2005 |
Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2005 |
[No rebound psychosis in a case of switching from clozapine to quetiapine].
Topics: Adult; Antipsychotic Agents; Aripiprazole; Brain; Brief Psychiatric Rating Scale; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Humans; Male; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Dopamine D2; Schizophrenia; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2006 |
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Benzoxazoles; Binding, Competitive; Cell Line; Clozapine; Dioxanes; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; GTP-Binding Proteins; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; Humans; Male; Piperazines; Prolactin; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Serotonin 5-HT1 Receptor Agonists; Serotonin Receptor Agonists; Spodoptera; Sulfur Radioisotopes; Tropanes | 2006 |
Benefits of combining aripiprazole to clozapine: three case reports.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia, Disorganized; Schizophrenia, Paranoid | 2006 |
Clozapine augmentation with aripiprazole for negative symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Schizophrenic Psychology; Treatment Outcome | 2006 |
Atypical antipsychotics and pituitary tumors: a pharmacovigilance study.
Topics: Adolescent; Adverse Drug Reaction Reporting Systems; Amenorrhea; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Dibenzothiazepines; Female; Galactorrhea; Gynecomastia; Haloperidol; Humans; Hyperprolactinemia; Male; Olanzapine; Piperazines; Pituitary Neoplasms; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Sex Factors; Thiazoles; United States; United States Food and Drug Administration | 2006 |
A model of anticholinergic activity of atypical antipsychotic medications.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Binding Sites; Clozapine; Cognition Disorders; Dibenzothiazepines; Dose-Response Relationship, Drug; Female; Humans; Male; Neuropsychological Tests; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Receptors, Cholinergic; Risperidone; Schizophrenia; Thiazoles | 2006 |
Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 recept
Topics: Animals; Antiparkinson Agents; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzoxazoles; Clozapine; Discrimination Learning; Discrimination, Psychological; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Male; Oxazines; Piperazines; Quinolones; Rats; Rats, Wistar; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Dopamine D3 | 2007 |
Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Blood Glucose; Body Weight; Cholesterol; Clozapine; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Retrospective Studies; Schizophrenia; Schizophrenic Psychology | 2007 |
Does antipsychotic polypharmacy increase the risk for metabolic syndrome?
Topics: Adult; Age Factors; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Body Mass Index; Cholesterol, HDL; Clozapine; Cross-Sectional Studies; Dibenzothiazepines; Drug Therapy, Combination; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Thiazoles; Triglycerides | 2007 |
Aripiprazole augmentation of clozapine in treatment-resistant schizophrenia: a clinical observation.
Topics: Adult; Aripiprazole; Clozapine; Dopamine D2 Receptor Antagonists; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Avoidance Learning; Biomarkers; Brain; Brain Chemistry; Catalepsy; Clozapine; Dopamine Agonists; Drug Evaluation, Preclinical; Haloperidol; Male; Piperazines; Prolactin; Proto-Oncogene Proteins c-fos; Psychotic Disorders; Quinolones; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, Serotonin, 5-HT2; Serotonin Antagonists; Treatment Outcome | 2007 |
The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Haloperidol; Male; Mice; Neural Inhibition; Olanzapine; Phencyclidine; Piperazines; Quinolones; Receptors, Dopamine D2; Reflex, Startle; Schizophrenia | 2007 |
Indexing of reports on aripiprazole augmentation of clozapine.
Topics: Abstracting and Indexing; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Information Services; Information Storage and Retrieval; Piperazines; Quinolones; Schizophrenia | 2007 |
Management of clozapine-induced obsessive-compulsive symptoms in a man with schizophrenia.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia, Paranoid | 2007 |
Augmentation of clozapine treatment with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Piperazines; Psychotic Disorders; Quinolones; Treatment Outcome | 2007 |
Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Topics: Adenylyl Cyclases; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzoxazoles; Carrier Proteins; Chlorocebus aethiops; Clozapine; COS Cells; Cricetinae; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Drug Interactions; Piperazines; Piperidines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Transfection | 2007 |
Effect of antipsychotics on succinate dehydrogenase and cytochrome oxidase activities in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Electron Transport Complex IV; Energy Metabolism; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Succinate Dehydrogenase | 2007 |
Augmentation of aripiprazole with low-dose clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Sleep; Treatment Outcome | 2007 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Databases, Factual; Dementia; Dibenzothiazepines; Drug Utilization Review; Health Services for the Aged; Humans; Olanzapine; Pharmaceutical Services; Piperazines; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Stroke; Thiazoles; Treatment Outcome | 2007 |
Repeated creatine kinase elevation under treatment with quetiapine, clozapine, and aripiprazole in an adolescent.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Creatine Kinase; Dibenzothiazepines; Humans; Male; Personality Disorders; Piperazines; Quetiapine Fumarate; Quinolones; Schizophrenia, Paranoid; Treatment Outcome | 2007 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia | 2009 |
Use of Aripiprazole in treatment resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2008 |
Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Body Mass Index; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Fasting; Feeding Behavior; Female; Glucose; Glucose Tolerance Test; Humans; Incidence; Insulin; Male; Middle Aged; Olanzapine; Piperazines; Prevalence; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Time Factors | 2008 |
Antipsychotic-induced oxidative stress in rat brain.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain; Clozapine; Corpus Striatum; Haloperidol; Hippocampus; Male; Olanzapine; Oxidative Stress; Piperazines; Prefrontal Cortex; Quinolones; Rats; Rats, Wistar; Superoxides; Thiobarbituric Acid Reactive Substances | 2008 |
Lack of effect of antipsychotics on BNDF and NGF levels in hippocampus of Wistar rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Drug Administration Schedule; Haloperidol; Hippocampus; Male; Nerve Growth Factor; Olanzapine; Piperazines; Quinolones; Rats; Rats, Wistar; Time; Up-Regulation | 2008 |
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Benzofurans; Benzoxazoles; Benzylamines; Blood Glucose; Clozapine; Corticosterone; Cyclopentanes; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Haloperidol; Male; Olanzapine; Piperazines; Quinolones; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Thiazoles | 2008 |
Role of serotonin-1A receptors in the action of antipsychotic drugs: comparison of prepulse inhibition studies in mice and rats and relevance for human pharmacology.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Haloperidol; Inhibition, Psychological; Male; Mice; Mice, Inbred Strains; Olanzapine; Piperazines; Quinolones; Rats; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Serotonin Receptor Agonists; Species Specificity | 2008 |
A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Feasibility Studies; Female; Follow-Up Studies; Humans; Male; Netherlands; Olanzapine; Overweight; Piperazines; Quinolones; Schizophrenia | 2008 |
Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Schizophrenia, Paranoid; Weight Gain | 2008 |
Is a high dosage aripiprazole-clozapine combination an effective strategy for treatment-resistant schizophrenic patients? A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Resistance; Drug Therapy, Combination; Humans; Male; Metabolic Syndrome; Piperazines; Quinolones; Schizophrenia, Paranoid | 2009 |
Extreme elevation of creatinine phosphokinase levels in neuroleptic malignant syndrome associated with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Creatine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Humans; Male; Myocardial Infarction; Neuroleptic Malignant Syndrome; Piperazines; Quinolones; Risperidone; Schizophrenia; Valproic Acid | 2009 |
Successful switch from clozapine to aripiprazole: a case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Administration Schedule; Drug Resistance; Humans; Male; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2009 |
Aripiprazole-induced agitation after clozapine discontinuation: a case report.
Topics: Akathisia, Drug-Induced; Alcoholism; Antipsychotic Agents; Aripiprazole; Clozapine; Cocaine-Related Disorders; Comorbidity; Delayed-Action Preparations; Diabetic Ketoacidosis; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Middle Aged; Molindone; Piperazines; Quinolones; Schizophrenia, Paranoid; Substance Withdrawal Syndrome | 2009 |
Haloperidol changes mRNA expression of a QKI splice variant in human astrocytoma cells.
Topics: Alternative Splicing; Antipsychotic Agents; Aripiprazole; Astrocytoma; Benzodiazepines; Cell Line, Tumor; Clozapine; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Receptors, Dopamine D2; Reverse Transcriptase Polymerase Chain Reaction; Risperidone; RNA-Binding Proteins; RNA, Messenger; Time Factors | 2009 |
Aripiprazole in treatment-refractory schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Brief Psychiatric Rating Scale; Clozapine; Consciousness Disorders; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Hospitalization; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology | 2009 |
Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Aripiprazole; Benzamides; Benzodiazepines; Benzoxazoles; Catalepsy; Clozapine; Dibenzothiazepines; Dioxanes; Dopamine Antagonists; Female; Haloperidol; Macaca fascicularis; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Remoxipride; Risperidone; Serotonin Receptor Agonists; Thiazoles; Tropanes; Video Recording | 2009 |
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States | 2009 |
Second-generation antipsychotic-associated diabetes mellitus and diabetic ketoacidosis: mechanisms, predictors, and screening need.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Diabetic Ketoacidosis; Dibenzothiazepines; Humans; Mass Screening; Olanzapine; Piperazines; Predictive Value of Tests; Prospective Studies; Quetiapine Fumarate; Quinolones; Severity of Illness Index | 2009 |
Aripiprazole as an adjunct to clozapine therapy in adolescents with early-onset schizophrenia: a retrospective chart review.
Topics: Adolescent; Age of Onset; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome; Young Adult | 2009 |
The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Topics: Amphetamine; Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Catalepsy; Clozapine; Disease Models, Animal; Dizocilpine Maleate; Dopamine Plasma Membrane Transport Proteins; Glycine Plasma Membrane Transport Proteins; Hyperkinesis; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Piperazines; Quinolones; Receptors, N-Methyl-D-Aspartate | 2010 |
Remission of schizophrenia psychosis and strong reduction of obsessive-compulsive disorder after adding clozapine to aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones; Schizophrenia; Young Adult | 2009 |
Clozapine-aripiprazole association in a 7-year-old girl with schizophrenia: clinical efficacy and successful management of neutropenia with lithium.
Topics: Antimanic Agents; Antipsychotic Agents; Aripiprazole; Child; Clozapine; Female; Humans; Lithium Carbonate; Neutropenia; Piperazines; Quinolones; Schizophrenia | 2009 |
Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2010 |
Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Drug Resistance; HEK293 Cells; Humans; Mutagenesis, Site-Directed; Neuroleptic Malignant Syndrome; Nursing Research; Olanzapine; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Quetiapine Fumarate; Quinolones; Receptor, Serotonin, 5-HT2A; Risperidone; Thiazoles | 2011 |
Use of aripiprazole in clozapine induced enuresis: report of two cases.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Enuresis; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia, Paranoid | 2010 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Drug Utilization; Evidence-Based Medicine; Female; Humans; Infant; Insurance Claim Review; Male; Medicaid; Mental Disorders; Off-Label Use; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2010 |
Drug-induced Pisa syndrome associated with aripiprazole during clozapine treatment.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2010 |
Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Quinolones; Schizophrenia; Schizophrenia, Paranoid; Treatment Failure; Young Adult | 2010 |
[Difficulties in changing drugs--from clozapine to aripiprazole in ambulatory care].
Topics: Ambulatory Care; Antipsychotic Agents; Aripiprazole; Clozapine; Depressive Disorder, Major; Drug Administration Schedule; Humans; Interpersonal Relations; Male; Middle Aged; Obesity; Patient Education as Topic; Patient Satisfaction; Piperazines; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Spouses | 2010 |
Neuroleptic malignant syndrome secondary to aripiprazole initiation in a clozapine-intolerant patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Isoxazoles; Neuroleptic Malignant Syndrome; Paliperidone Palmitate; Piperazines; Pyrimidines; Quinolones; Schizophrenia | 2010 |
Worsening psychosis after adding aripiprazole to clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Synergism; Humans; Male; Piperazines; Psychotic Disorders; Quinolones | 2011 |
Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs.
Topics: Adult; Age Factors; Alleles; Amisulpride; Anthropometry; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Body Mass Index; CLOCK Proteins; Clozapine; Dibenzothiazepines; Drug Therapy, Combination; Female; Genetic Association Studies; Genetic Carrier Screening; Genotype; Humans; Long-Term Care; Male; Middle Aged; Mutation, Missense; Olanzapine; Period Circadian Proteins; Piperazines; Polymorphism, Single Nucleotide; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Receptor, Melanocortin, Type 3; Receptors, Glucocorticoid; Receptors, Leptin; Risperidone; Schizophrenia; Sex Factors; Sulpiride; Syndecan-3 | 2011 |
Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Clozapine; Constipation; Enema; Fecal Impaction; Female; Gastrointestinal Agents; Humans; Lactulose; Male; Middle Aged; Piperazines; Polyethylene Glycols; Prevalence; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Severity of Illness Index; Young Adult | 2011 |
Add-on of aripiprazole improves outcome in clozapine-resistant schizophrenia.
Topics: Activities of Daily Living; Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Clozapine; Dose-Response Relationship, Drug; Drug Resistance; Female; Humans; Linear Models; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Social Behavior; Treatment Outcome; Young Adult | 2011 |
Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Germany; Humans; Male; Matched-Pair Analysis; Obsessive-Compulsive Disorder; Olanzapine; Piperazines; Prevalence; Quinolones; Schizophrenia; Serotonin Antagonists; Severity of Illness Index; Sulpiride | 2011 |
Influence of prenatal undernutrition on the effects of clozapine and aripiprazole in the adult male rats: relevance to a neurodevelopmental origin of schizophrenia?
Topics: Animals; Antipsychotic Agents; Aripiprazole; Body Weight; Clozapine; Disease Susceptibility; Eating; Female; Gene Expression Regulation; Hormones; Hypothalamus; Male; Malnutrition; Nervous System; Obesity; Piperazines; Pregnancy; Prenatal Nutritional Physiological Phenomena; Quinolones; Rats; Rats, Wistar; Schizophrenia | 2011 |
Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bipolar Disorder; Clozapine; Crime; Delayed-Action Preparations; Dibenzothiazepines; Female; Florida; Humans; Isoxazoles; Male; Medicaid; Middle Aged; Olanzapine; Outpatients; Paliperidone Palmitate; Piperazines; Propensity Score; Pyrimidines; Quetiapine Fumarate; Quinolones; Risk Factors; Risperidone; Schizophrenia; Treatment Outcome; United States; Young Adult | 2011 |
Aripiprazole augmentation in clozapine-associated obsessive-compulsive symptoms.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Piperazines; Quinolones | 2011 |
Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Dopamine Agonists; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Haloperidol; Male; Piperazines; Prolactin; Quetiapine Fumarate; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2 | 2012 |
In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Topics: Animals; Aripiprazole; CHO Cells; Clozapine; Cricetinae; Cricetulus; Cyclic AMP; Dopamine; Drug Partial Agonism; Humans; Organic Chemicals; Piperazines; Quinolones; Receptors, Dopamine D2; Receptors, Dopamine D3; Substrate Specificity | 2011 |
[Clinical characteristics of cannabis-induced schizophrenia spectrum disorder].
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Dibenzothiazepines; Hallucinations; Haloperidol; Humans; Hungary; Male; Marijuana Abuse; Olanzapine; Paranoid Disorders; Piperazines; Psychomotor Performance; Quetiapine Fumarate; Quinolones; Retrospective Studies; Risperidone; Schizophrenia; Schizophrenic Psychology | 2011 |
Effects of amisulpride and aripiprazole on progressive-ratio schedule performance: comparison with clozapine and haloperidol.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Conditioning, Operant; Dopamine Antagonists; Dose-Response Relationship, Drug; Female; Haloperidol; Kinetics; Models, Biological; Motor Activity; Motor Skills; Piperazines; Quinolones; Rats; Rats, Wistar; Reaction Time; Reinforcement Schedule; Serotonin Antagonists; Sulpiride | 2012 |
The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chi-Square Distribution; Clozapine; Dibenzothiazepines; Humans; Missouri; Olanzapine; Piperazines; Practice Patterns, Physicians'; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Schizophrenia; Thiazoles; Treatment Outcome | 2012 |
Effects of aripiprazole and clozapine on the treatment of glycolytic carbon in PC12 cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Antipsychotic Agents; Apoptosis; Aripiprazole; Carbon; Cell Survival; Clozapine; Dihydrolipoamide Dehydrogenase; Dose-Response Relationship, Drug; Electron Transport Complex IV; Extracellular Fluid; Gene Expression Regulation, Enzymologic; Glucose; Glycolysis; Hypoxanthine Phosphoribosyltransferase; Isocitrate Dehydrogenase; Ketone Oxidoreductases; Lactic Acid; Membrane Potential, Mitochondrial; NAD; Oxidoreductases; PC12 Cells; Piperazines; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Pyruvic Acid; Quinolones; Rats; RNA, Messenger; Time Factors | 2012 |
Discriminative stimulus properties of N-desmethylclozapine, the major active metabolite of the atypical antipsychotic clozapine, in C57BL/6 mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Discrimination Learning; Generalization, Psychological; Haloperidol; Male; Mice; Mice, Inbred C57BL; Piperazines; Quinolones | 2012 |
Impact of switching or initiating antipsychotic treatment on body weight during a 6-month follow-up in a cohort of patients with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Clozapine; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Olanzapine; Piperazines; Prospective Studies; Quinolones; Risperidone; Schizophrenia; Weight Loss | 2012 |
Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study).
Topics: Adult; Amisulpride; Antioxidants; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Catalase; Clozapine; Dibenzothiazepines; Enzyme Activation; Erythrocytes; Glutathione Peroxidase; Glutathione Reductase; Humans; Imidazoles; Indoles; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Sulpiride; Superoxide Dismutase; Superoxide Dismutase-1; Thiazoles; Treatment Outcome; Young Adult | 2013 |
Aripiprazole augmentation for clozapine-associated tardive torticollis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia; Torticollis; Treatment Outcome | 2012 |
Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Astemizole; Behavior, Animal; Benzodiazepines; Clozapine; Dose-Response Relationship, Drug; Drug Interactions; Energy Metabolism; Epoxy Compounds; Fatty Acids; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Motor Activity; Olanzapine; Oxygen Consumption; Piperazines; Quinolones; Receptors, Histamine H1; Respiration; Risperidone; Terfenadine; Time Factors | 2014 |
Metabolic syndrome and antipsychotic monotherapy treatment among schizophrenia patients in Malaysia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Female; Flupenthixol; Humans; Malaysia; Male; Metabolic Syndrome; Middle Aged; Piperazines; Quinolones; Schizophrenia; Trifluoperazine; Waist Circumference; Young Adult | 2013 |
LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Effectiveness of a clozapine-aripiprazole combination in Tourette syndrome and bipolar spectrum disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Therapy, Combination; Humans; Male; Piperazines; Quinolones; Tourette Syndrome | 2013 |
Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Cattle; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Drug Stability; Female; Forensic Toxicology; Hemolysis; Humans; Isoxazoles; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Pyrimidines; Quetiapine Fumarate; Quinolones; Reproducibility of Results; Risperidone; Saliva; Serum; Sulpiride; Tandem Mass Spectrometry | 2013 |
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Huntington Disease; Male; Morpholines; Piperazines; Psychotic Disorders; Quinolones; Reboxetine; Treatment Outcome | 2013 |
Clozapine-induced restless legs syndrome treated with aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Restless Legs Syndrome; Schizophrenia, Paranoid | 2013 |
Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Comorbidity; Cost-Benefit Analysis; Diabetes Mellitus; Hospitalization; Humans; Isoindoles; Lurasidone Hydrochloride; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Piperazines; Quinolones; Recurrence; Schizophrenia; Thiazoles; United States | 2013 |
A case report of partial bowel obstruction after aripiprazole addition to clozapine in a young male with schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Defecation; Drug Substitution; Drug Therapy, Combination; Humans; Intestinal Obstruction; Lamotrigine; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Treatment Outcome; Triazines | 2013 |
Hypochondriasis and obsessive-compulsive disorder in schizophrenic patients treated with clozapine vs other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Comorbidity; Female; Humans; Hypochondriasis; Male; Middle Aged; Obsessive-Compulsive Disorder; Olanzapine; Paliperidone Palmitate; Prevalence; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Sulpiride | 2014 |
The effects of antipsychotic switching on diabetes in chronic schizophrenia.
Topics: Antipsychotic Agents; Aripiprazole; Blood Glucose; Clozapine; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Obesity; Piperazines; Quinolones; Schizophrenia; Treatment Outcome; Weight Loss | 2014 |
Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: a 12-month prospective study.
Topics: Adult; Alkaline Phosphatase; Antipsychotic Agents; Aripiprazole; Bone Density; Chlorpromazine; Clozapine; Dibenzothiazepines; Estrogens; Female; Humans; Male; Middle Aged; Osteoporosis; Perphenazine; Piperazines; Prolactin; Prospective Studies; Quetiapine Fumarate; Quinolones; Risk Factors; Schizophrenia; Sulpiride | 2014 |
Aripiprazole for the treatment of a manic patient with clozapine-related colonic obstruction receiving total colectomy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Colectomy; Humans; Intestinal Obstruction; Male; Piperazines; Quinolones | 2014 |
High doses of aripiprazole therapy for a patient with treatment-resistant schizophrenia responsive to, but intolerant of, clozapine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2015 |
Increased orbitofrontal cortex activation associated with "pro-obsessive" antipsychotic treatment in patients with schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Brain Mapping; Clozapine; Executive Function; Female; Humans; Inhibition, Psychological; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Obsessive Behavior; Olanzapine; Piperazines; Prefrontal Cortex; Psychiatric Status Rating Scales; Psychomotor Performance; Quinolones; Schizophrenia; Sulpiride | 2015 |
Comparative analysis of the treatment of chronic antipsychotic drugs on epileptic susceptibility in genetically epilepsy-prone rats.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Disease Models, Animal; Epilepsy; Haloperidol; Mental Disorders; Olanzapine; Quetiapine Fumarate; Rats; Risperidone; Seizures | 2015 |
Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Drug Substitution; Humans; Italy; Piperazines; Quinolones; Schizophrenia | 2015 |
Partial agonism and fast dissociation of LASSBio-579 at dopamine D2 receptor.
Topics: Antipsychotic Agents; Aripiprazole; Cell Membrane; Clozapine; Corpus Striatum; Dopamine Agonists; Guanosine 5'-O-(3-Thiotriphosphate); Haloperidol; HEK293 Cells; Humans; Kinetics; Piperazines; Radioligand Assay; Receptors, Dopamine D2; Transfection | 2015 |
Bethanechol and Aripiprazole for the management of refractory urinary incontinence in a patient on Clozapine.
Topics: Antipsychotic Agents; Aripiprazole; Bethanechol; Clozapine; Female; Humans; Middle Aged; Schizophrenia; Urinary Incontinence | 2016 |
Effective Use of Aripiprazole Augmentation in a Clozapine-Treated Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Clozapine; Drug Therapy, Combination; Humans; Male | 2015 |
Remission of irreversible aripiprazole-induced tardive dystonia with clozapine: a case report.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Clozapine; Dyskinesia, Drug-Induced; Humans; Male; Movement Disorders; Neurologic Examination; Psychotic Disorders; Treatment Outcome; Young Adult | 2015 |
An observational study of clozapine induced sedation and its pharmacological management.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Cross-Sectional Studies; Humans; Hypnotics and Sedatives; Prospective Studies; Schizophrenia; Sleep; Treatment Outcome | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation; Cost-Benefit Analysis; Delayed-Action Preparations; Drug Administration Schedule; Humans; Injections, Intramuscular; Markov Chains; Models, Economic; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; State Medicine; United Kingdom | 2015 |
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 2: Preclinical and Early Phase Human Proof of Concept Studies.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Clozapine; Depressive Disorder, Major; Dyskinesia, Drug-Induced; History, 20th Century; Humans; Male; United States; United States Food and Drug Administration | 2016 |
[Plasma levels of antipsychotics and the severity of side-effects in the treatment of schizophrenia exacerbation].
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Clozapine; Depression; Drug Therapy, Combination; Female; Haloperidol; Humans; Hyperprolactinemia; Male; Middle Aged; Olanzapine; Prolactin; Risperidone; Schizophrenia; Schizophrenic Psychology; Young Adult | 2015 |
Hyperprolactinemia, prolactin-related side effects and quality of life in Chinese psychiatric patients.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Case-Control Studies; China; Clozapine; Female; Humans; Hyperprolactinemia; Male; Mental Disorders; Quality of Life; Risperidone; Sexual Dysfunction, Physiological; Young Adult | 2016 |
Combined Antipsychotics and Electroconvulsive Therapy in an Acutely Psychotic Patient with Treatment-resistant Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Combined Modality Therapy; Drug Therapy, Combination; Electroconvulsive Therapy; Female; Hospitalization; Humans; Psychiatric Status Rating Scales; Schizophrenia; Treatment Outcome | 2017 |
Effects of long-term treatment with haloperidol, clozapine and aripiprazole on mice isolated vas deferens.
Topics: Adenosine Triphosphate; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Haloperidol; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle, Smooth; Norepinephrine; Potassium Chloride; Random Allocation; Serotonin; Vas Deferens | 2017 |
Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Bromodeoxyuridine; Cell Count; Clozapine; Haloperidol; Hippocampus; Immunohistochemistry; Male; Mice, Inbred C57BL; Neurogenesis; Neurons; Olanzapine; Quetiapine Fumarate | 2017 |
[Efficacy of low-Dose Aripiprazole to Treat Clozapine-Associated Tardive Dystonia in a Patient with Schizophrenia].
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diagnosis, Differential; Female; Humans; Middle Aged; Schizophrenia; Tardive Dyskinesia | 2017 |
Effective Switch From Clozapine to Aripiprazole in Treatment-Resistant Schizophrenia and Comorbid Alcohol Use Disorder.
Topics: Aged; Alcoholism; Antipsychotic Agents; Aripiprazole; Clozapine; Comorbidity; Drug Substitution; Humans; Male; Schizophrenia | 2017 |
Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood; Clozapine; Female; Humans; Lipid Peroxidation; Male; Olanzapine; Piperazines; Quetiapine Fumarate; Risperidone; Thiazoles; Thiobarbituric Acid Reactive Substances; Young Adult | 2018 |
Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine.
Topics: Animals; Aripiprazole; Cerebral Cortex; Clozapine; Dendritic Spines; Disks Large Homolog 4 Protein; Dose-Response Relationship, Drug; Glycogen Synthase Kinase 3 beta; Haloperidol; Indoles; Maleimides; Phosphorylation; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction | 2018 |
Electroencephalogram Modifications Associated With Atypical Strict Antipsychotic Monotherapies.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Cerebral Cortex; Clozapine; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Psychotic Disorders; Quetiapine Fumarate; Risperidone; Schizophrenia; Young Adult | 2018 |
Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Male; Obsessive-Compulsive Disorder; Schizophrenia | 2019 |
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Readmission; Polypharmacy; Schizophrenia; Treatment Outcome | 2019 |
Antipsychotics differentially regulate insulin, energy sensing, and inflammation pathways in hypothalamic rat neurons.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Hypothalamus; Inflammation; Insulin; Insulin Resistance; MAP Kinase Signaling System; Neurons; Olanzapine; Phosphorylation; Rats; Schizophrenia; Signal Transduction | 2019 |
Prenatal treatment with methylazoxymethanol acetate as a neurodevelopmental disruption model of schizophrenia in mice.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Behavior, Animal; Clozapine; Disease Models, Animal; Female; Haloperidol; Hippocampus; Methylazoxymethanol Acetate; Mice; Motor Activity; Pregnancy; Prenatal Exposure Delayed Effects; Prepulse Inhibition; Risperidone; Schizophrenia | 2019 |
Discriminative stimulus properties of the typical antipsychotic haloperidol compared to other antipsychotic drugs in C57BL/6 mice.
Topics: Amisulpride; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Haloperidol; Male; Mice; Mice, Inbred C57BL | 2019 |
Effect fingerprints of antipsychotic drugs on neural networks in vitro.
Topics: Action Potentials; Animals; Animals, Newborn; Antipsychotic Agents; Aripiprazole; Cells, Cultured; Cerebral Cortex; Clozapine; Dose-Response Relationship, Drug; Haloperidol; Mice; Mice, Inbred C57BL; Nerve Net | 2019 |
Direct effects of antipsychotic drugs on insulin, energy sensing and inflammatory pathways in hypothalamic mouse neurons.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Cell Line; Clozapine; Energy Metabolism; Heterocyclic Compounds; Hypothalamus; Inflammation; Insulin; Mice; Neurons; Olanzapine; Phosphorylation; Signal Transduction | 2019 |
Development of an Integrated Tissue Pretreatment Protocol for Enhanced MALDI MS Imaging of Drug Distribution in the Brain.
Topics: Animals; Aripiprazole; Brain; Brain Chemistry; Central Nervous System Agents; Clozapine; Donepezil; Haloperidol; Male; Mice; Mice, Inbred C57BL; Peritoneum; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tacrine; Tissue Distribution | 2020 |
The 12-year trend report of antipsychotic usage in a nationwide claims database derived from four million people in Japan.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Clozapine; Delayed-Action Preparations; Humans; Japan; Schizophrenia | 2020 |
Identification and Quantification of Antipsychotics in Blood Samples by LC-MS-MS: Case Reports and Data from Three Years of Routine Analysis.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chromatography, Liquid; Clozapine; Dibenzothiazepines; Female; Forensic Toxicology; Humans; Male; Olanzapine; Paliperidone Palmitate; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia; Substance Abuse Detection; Suicide; Sulpiride; Tandem Mass Spectrometry; Thiazoles | 2020 |
Infection is associated with elevated serum concentrations of antipsychotic drugs.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Quetiapine Fumarate; Respiratory Tract Infections; Risperidone | 2021 |
Aripiprazole LAI two-injection start in a 16 year-old adolescent with schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Male; Schizophrenia | 2022 |
Orexin-a elevation in antipsychotic-treated compared to drug-free patients with schizophrenia: A medication effect independent of metabolic syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Clozapine; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Orexins; Prospective Studies; Schizophrenia | 2022 |
A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Quinolones; Schizophrenia; Schizophrenia, Treatment-Resistant; Thiophenes; Young Adult | 2022 |
The relationship of antipsychotic treatment with reduced brown adipose tissue activity in patients with schizophrenia.
Topics: Adipose Tissue, Brown; Antipsychotic Agents; Aripiprazole; Clozapine; Humans; Metabolic Syndrome; Schizophrenia; Thermogenesis | 2022 |
Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Topics: Adolescent; Adult; Aged; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Clozapine; Drug-Related Side Effects and Adverse Reactions; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Quetiapine Fumarate; Retrospective Studies; Risperidone; Schizophrenia | 2022 |
Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Topics: Adenosine Monophosphate; Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chlorpromazine; Clopenthixol; Clozapine; Flupenthixol; Fluphenazine; Haloperidol; Humans; Olanzapine; Paliperidone Palmitate; Pharmaceutical Preparations; Pimozide; Quetiapine Fumarate; Risperidone; Sulpiride; Trifluoperazine | 2022 |
Effects of Psychotropic Drugs on Ribosomal Genes and Protein Synthesis.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Humans; Lithium; Olanzapine; Psychotropic Drugs; Quetiapine Fumarate; Ribosomes | 2022 |
Unique effect of clozapine on adenosine A
Topics: Adenosine; Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dopamine; Humans; Mammals; Receptors, Dopamine D2 | 2023 |
The impact of adjunctive aripiprazole on QT interval: A 12-week open label study in patients on olanzapine, clozapine or risperidone.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Humans; Olanzapine; Piperazines; Prospective Studies; Risperidone | 2023 |
Atypical antipsychotics attenuate MK801-induced social withdrawal and hyperlocomotion in the RHA rat model of schizophrenia-relevant features.
Topics: Animals; Antipsychotic Agents; Aripiprazole; Clozapine; Dizocilpine Maleate; Male; Rats; Schizophrenia; Social Isolation | 2023 |